Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Tools & Technology › Informatics › Franciscan Health to Use Deep Lens for Enrollment in Precision Cancer Drug Trials

Franciscan Health to Use Deep Lens for Enrollment in Precision Cancer Drug Trials

Aug 20, 2020
|
staff reporter

NEW YORK – Franciscan Health Cancer Center in Indianapolis has enlisted startup bioinformatics technology vendor Deep Lens to improve clinical trial enrollment and participation in studies investigating precision oncology drugs.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Mar
23
Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
30
Featured Webinar

Circulating Tumor Cells in Breast Cancer: Understanding a Validated Diagnostic Tool for Precision Medicine

Sponsored by
Menarini Silicon Biosystems

This webinar will provide an overview of the current state of circulating tumor cell (CTC) enumeration for clinical use in metastatic breast cancer.

Apr
08
Featured Webinar

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.

What's Popular?

In Informatics

  1. Nonprofit Count Me In to Return Genomic Results to Patients With Rare Cancers

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.